Target Price | €178.00 |
Price | €131.40 |
Potential | 35.46% |
Number of Estimates | 15 |
15 Analysts have issued a price target Merck 2026 . The average Merck target price is €178.00. This is 35.46% higher than the current stock price. The highest price target is €206.00 56.77% , the lowest is €160.00 21.77% . | |
A rating was issued by 17 analysts: 14 Analysts recommend Merck to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Merck stock has an average upside potential 2026 of 35.46% . Most analysts recommend the Merck stock at Purchase. |
14 Analysts have issued a sales forecast Merck 2025 . The average Merck sales estimate is €22.0b . This is 4.17% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €22.4b 5.74% , the lowest is €21.2b 0.21% .
This results in the following potential growth metrics:
2024 | €21.2b | 0.78% |
---|---|---|
2025 | €22.0b | 4.17% |
2026 | €23.0b | 4.37% |
2027 | €23.9b | 3.78% |
2028 | €25.3b | 5.86% |
2029 | €26.7b | 5.74% |
14 Analysts have issued an Merck EBITDA forecast 2025. The average Merck EBITDA estimate is €6.4b . This is 4.19% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €6.6b 0.84% , the lowest is €6.1b 8.41% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €6.2b | 5.89% |
---|---|---|
2025 | €6.4b | 3.45% |
2026 | €6.8b | 7.03% |
2027 | €7.1b | 4.58% |
2028 | €7.6b | 5.97% |
2029 | €8.1b | 6.48% |
2024 | 29.15% | 5.07% |
---|---|---|
2025 | 28.95% | 0.70% |
2026 | 29.69% | 2.56% |
2027 | 29.92% | 0.77% |
2028 | 29.95% | 0.10% |
2029 | 30.16% | 0.70% |
11 Merck Analysts have issued a net profit forecast 2025. The average Merck net profit estimate is €3.3b . This is 18.98% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €3.6b 28.55% , the lowest is €3.1b 11.50% .
This results in the following potential growth metrics and future Net Margins:
2024 | €2.8b | 1.69% |
---|---|---|
2025 | €3.3b | 18.98% |
2026 | €3.7b | 10.89% |
2027 | €4.0b | 7.84% |
2028 | €4.3b | 8.89% |
2029 | €4.7b | 8.62% |
2024 | 13.13% | 2.45% |
---|---|---|
2025 | 15.00% | 14.22% |
2026 | 15.94% | 6.27% |
2027 | 16.56% | 3.89% |
2028 | 17.03% | 2.84% |
2029 | 17.50% | 2.76% |
11 Analysts have issued a Merck forecast for earnings per share. The average Merck EPS is €7.60 . This is 18.94% higher than earnings per share in the financial year 2024. The highest EPS forecast is €8.21 28.48% , the lowest is €7.13 11.58% .
This results in the following potential growth metrics and future valuations:
2024 | €6.39 | 1.69% |
---|---|---|
2025 | €7.60 | 18.94% |
2026 | €8.43 | 10.92% |
2027 | €9.09 | 7.83% |
2028 | €9.90 | 8.91% |
2029 | €10.75 | 8.59% |
Current | 20.57 | 14.79% |
---|---|---|
2025 | 17.28 | 15.99% |
2026 | 15.59 | 9.78% |
2027 | 14.45 | 7.31% |
2028 | 13.27 | 8.17% |
2029 | 12.22 | 7.91% |
Based on analysts' sales estimates for 2025, the Merck stock is valued at an EV/Sales of 2.95 and an P/S ratio of 2.59 .
This results in the following potential growth metrics and future valuations:
Current | 3.07 | 15.19% |
---|---|---|
2025 | 2.95 | 3.94% |
2026 | 2.83 | 4.18% |
2027 | 2.72 | 3.64% |
2028 | 2.57 | 5.54% |
2029 | 2.43 | 5.42% |
Current | 2.70 | 16.87% |
---|---|---|
2025 | 2.59 | 4.00% |
2026 | 2.48 | 4.19% |
2027 | 2.39 | 3.64% |
2028 | 2.26 | 5.53% |
2029 | 2.14 | 5.43% |
Analyst | Rating | Action | Date |
---|---|---|---|
STIFEL EUROPE |
Buy
➜
Buy
|
Unchanged | Dec 15 2024 |
BNP PARIBAS EXANE |
Neutral
➜
Neutral
|
Unchanged | Dec 04 2024 |
DZ BANK |
Buy
➜
Buy
|
Unchanged | Dec 02 2024 |
HSBC |
Buy
➜
Buy
|
Unchanged | Nov 24 2024 |
EQUITA SIM |
Buy
➜
Buy
|
Unchanged | Nov 18 2024 |
ODDO BHF |
Buy
➜
Buy
|
Unchanged | Nov 14 2024 |
DAY BY DAY |
Buy
➜
Sell
|
Downgrade | Oct 30 2024 |
Analyst Rating | Date |
---|---|
Unchanged
STIFEL EUROPE:
Buy
➜
Buy
|
Dec 15 2024 |
Unchanged
BNP PARIBAS EXANE:
Neutral
➜
Neutral
|
Dec 04 2024 |
Unchanged
DZ BANK:
Buy
➜
Buy
|
Dec 02 2024 |
Unchanged
HSBC:
Buy
➜
Buy
|
Nov 24 2024 |
Unchanged
EQUITA SIM:
Buy
➜
Buy
|
Nov 18 2024 |
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Nov 14 2024 |
Downgrade
DAY BY DAY:
Buy
➜
Sell
|
Oct 30 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.